New obesity discovery rewrites decades of fat science
May 8, 2026 / Obesity research / Metabolic disease / Fat metabolism / Lipodystrophy / Adipose tissue
Researchers discovered that the fat-regulating protein HSL also maintains adipose cell health within the nucleus, with deficiency linked to lipodystrophy rather than obesity, reshaping understanding of fat metabolism and metabolic disease biology.
Alcohol use disorder and obesity may cause metabolic alterations that raise the risk of relapse, study suggests
May 11, 2026 / Alcohol use disorder / GLP-1 agonists / Obesity research / Metabolic dysfunction / Addiction treatment
Researchers found obesity-related metabolic dysfunction may intensify alcohol cravings and relapse risk in alcohol use disorder, supporting investigation of GLP-1 therapies targeting shared metabolic and reward pathways involved in addiction and obesity.
Obesity Could Drive Alzheimer’s Disease Before Symptoms Appear
May 7, 2026 / Alzheimer’s disease / Obesity research / Metabolic dysfunction / Neurodegeneration / Brain health
A new review links obesity-related metabolic dysfunction to early Alzheimer’s disease development, highlighting shared disruptions in insulin signaling, adipose tissue communication, and mitochondrial function that may contribute to neurodegeneration before symptoms emerge.
Bariatric surgery outperforms GLP-1 medications for obesity disease remission
May 6, 2026 / Bariatric surgery / GLP-1 therapy / Obesity treatment / Type 2 diabetes / Metabolic health
A large real-world analysis found bariatric surgery produced substantially greater weight loss and higher remission rates for diabetes, hypertension, and hyperlipidemia than GLP-1 therapies in patients with obesity.
Study points to metabolic health as a key factor in mood disorders
May 11, 2026 / Bipolar disorder / Metabolic health / Insulin resistance / Cognitive impairment / GLP-1 therapies
Researchers found metabolic dysfunction, including insulin resistance and leptin dysregulation, is strongly linked to cognitive impairment and brain structure changes in bipolar disorder, highlighting metabolic health as a potential therapeutic target in mood disorders.
New Research Finds This Common Sugar May Be a Key Contributor to Weight Gain
May 11, 2026 / Fructose metabolism / Obesity research / Metabolic syndrome / Insulin resistance / Cardiovascular disease
A new review found fructose uniquely disrupts metabolic regulation by increasing fat synthesis, depleting cellular energy, and promoting obesity, diabetes, and cardiovascular risk beyond its role as a dietary calorie source.
GLP-1 use surges as surgery rates drop for severe obesity
May 5, 2026 / GLP-1 medications / Bariatric surgery / Severe obesity / Weight loss treatment / Metabolic health
GLP-1 prescriptions for severe obesity surged dramatically between 2018 and 2025 as bariatric surgery rates declined, highlighting changing treatment preferences alongside persistent underdiagnosis and undertreatment of obesity across the healthcare system.
Scientists say this common sweetener may be quietly rewiring your metabolism
May 11, 2026 / Fructose metabolism / Obesity research / Insulin resistance / Metabolic disease / Cardiovascular health
A new review found fructose may disrupt metabolic regulation by promoting fat storage, impairing cellular energy balance, and increasing risks for obesity, insulin resistance, and cardiovascular disease beyond its caloric contribution alone.
Distinct metabolic signature found in patients with heart failure with preserved ejection fraction
May 5, 2026 / HFpEF / Heart failure / Cardiometabolic disease / Glucose metabolism / Precision medicine
Researchers identified a unique metabolic fingerprint in obese patients with HFpEF, marked by disrupted glucose metabolism and cardiac energy deficits, revealing potential therapeutic targets for this increasingly prevalent form of heart failure.
A new tool that predicts obesity-related disease risk beyond BMI
May 5, 2026 / Precision medicine / Obesity risk / Metabolic disease / Predictive analytics / Cardiometabolic health
Researchers developed OBSCORE, a predictive model that identifies individuals at highest risk for obesity-related complications using clinical and metabolic data, outperforming BMI alone in forecasting diabetes, cardiovascular, and other metabolic diseases.
Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs
May 6, 2026 / Bariatric surgery / GLP-1 therapy / Cardiometabolic health / Type 2 diabetes / Obesity treatment
Real-world data show bariatric surgery provides greater long-term cardiovascular, renal, and metabolic protection than GLP-1 therapies in older adults with obesity and diabetes, reinforcing surgery’s role as a powerful intervention beyond glycemic control alone.
Six genes found to connect pancreatic cancer with metabolic dysfunction
May 6, 2026 / Pancreatic cancer / Metabolic dysfunction / Type 2 diabetes / Obesity inflammation / Cancer biomarkers
Researchers identified six inflammatory genes linking pancreatic cancer, obesity, and type 2 diabetes, revealing shared metabolic and immune pathways that may drive tumor progression, recurrence, and poorer outcomes while offering new opportunities for biomarker development and targeted therapies.
U.S. bariatric surgery rates drop significantly amid GLP-1 surge
May 5, 2026 / Bariatric surgery / GLP-1 drugs / Obesity treatment / Metabolic disease / Weight-loss surgery
U.S. bariatric surgery rates fell more than 20% in 2024 as GLP-1 adoption accelerated, highlighting shifting obesity treatment patterns while reinforcing surgery’s continued role as the most effective long-term intervention for severe obesity and related metabolic disease.
Study links metabolic dysfunction to cognitive impairment in bipolar disorder
May 11, 2026 / Bipolar disorder / Metabolic dysfunction / Cognitive impairment / Insulin resistance / GLP-1 therapy
New research links insulin resistance and metabolic dysfunction to structural brain changes and cognitive impairment in bipolar disorder, highlighting metabolic health as a potential therapeutic target for improving memory, attention, and executive function in mood disorders.
Novo Nordisk Explores New Growth In Alcohol Use Disorder And Obesity
May 5, 2025 / Novo Nordisk / Alcohol use disorder / Semaglutide / GLP-1 therapy / Metabolic disease
Novo Nordisk is expanding beyond diabetes and obesity by investigating semaglutide for alcohol use disorder and advancing LX9851 for metabolic disease, reflecting growing interest in GLP-1 therapies targeting addiction, obesity, and broader cardiometabolic health pathways.
Virta Health CMO to Speak at Economics of Obesity and Metabolic Health Summit
May 6, 2026 / Virta Health / Obesity management / Metabolic health / Chronic disease care / Weight-loss economics
Virta Health’s participation in the Economics of Obesity and Metabolic Health Summit highlights growing focus on sustainable weight management, behavior change, and value-based chronic disease care as metabolic health becomes an increasingly important economic and healthcare priority.
Scientists discover hidden fat cell mechanism that could reshape obesity treatment
May 9, 2026 / Obesity research / Metabolic disease / Fat cell biology / Insulin resistance / Adipose tissue
Researchers discovered hormone-sensitive lipase (HSL) also regulates gene activity inside fat cell nuclei, revealing healthy adipose tissue function—not just fat quantity—as central to obesity, diabetes, and metabolic disease risk and future therapeutic development.
NIMS launches Comprehensive Obesity Clinic in Hyderabad
May 7, 2026 / Obesity clinic / Metabolic disorders / Weight management / Endocrinology care / Obesity treatment
NIMS launched a multidisciplinary obesity clinic in Hyderabad offering evidence-based management of obesity and metabolic disorders through endocrinology, nutrition, physical activity, behavioral support, and long-term follow-up, reflecting growing recognition of obesity as a chronic medical condition.
SureNano Science Advances GLP-1 Candidate GEP-44 as Obesity Drug Market Nears $200 Billion
May 11, 2025 / GLP-1 therapy / Obesity drugs / Metabolic disease / Triple agonist / Weight-loss treatment
SureNano is advancing GEP-44, a next-generation triple agonist targeting GLP-1 and peptide YY pathways, aiming to improve obesity treatment efficacy, tolerability, and delivery options as competition intensifies in the rapidly expanding metabolic disease therapeutics market.